Lifespan Vision Ventures, a Norwalk-based venture capital firm, is leading Remedium Bio, Inc.'s $10 million Series A financing to advance the company's durable protein therapeutics platform toward first-in-human clinical development.
Lifespan Vision Ventures invests in early-stage biotechnology companies developing technologies to prevent and treat age-related diseases, partnering with founders advancing science-driven solutions for healthy aging. The round's initial closing included participation from Eli Lilly and Company and HKX Capital, with Harry Robb of Lifespan Vision Ventures joining Remedium's Board of Directors.
Remedium is developing durable protein therapeutics enabling controlled, long-lasting expression of therapeutic proteins following minimally invasive subcutaneous administration, harnessing adipocytes as a durable site for protein production with potential multi-year benefit for patients with chronic diseases. The company's proprietary Prometheus platform aims to replace subcutaneously administered protein therapies with single-injection, adjustable gene therapies, with a pipeline targeting endocrinology, immunology, neurology, and musculoskeletal diseases.
Andrew Worden, Founding Partner of Lifespan Vision Ventures, said, "Remedium has built a differentiated platform with the potential to address important limitations of chronic biologic therapy. We are proud to lead the Series A financing and support the company as it advances its pipeline toward clinical development and expands the potential of its platform."
The financing will support advancement of Remedium's lead programs, continued platform expansion, and preparation for first-in-human clinical studies.
"Lifespan Vision Ventures shares our belief that durable therapies have the potential to fundamentally improve the treatment of chronic disease," said Frank Luppino, Chief Executive Officer of Remedium Bio. "We are excited to have them lead our Series A and to welcome Harry Robb to our Board as we advance our platform, expand our pipeline, and prepare for first-in-human clinical development."
